Literature DB >> 23910455

Adherence enhancing interventions for oral anticancer agents: a systematic review.

Tim Mathes1, Sunya-Lee Antoine, Dawid Pieper, Michaela Eikermann.   

Abstract

BACKGROUND: The use of oral anticancer agents has increased in the last decades. Adherence is a crucial factor for the success of oral anticancer agent therapy. However, many patients are non-adherent.
OBJECTIVE: The objective was to evaluate the effectiveness of adherence interventions in patients taking oral anticancer agents.
METHODS: A systematic literature search was performed in Medline and Embase. Titles and abstracts and in case of potential relevance, full-texts were assessed for eligibility according to the predefined inclusion criteria. The study quality was evaluated. Both process steps were carried out independently by two reviewers. Relevant data on study design, patients, interventions and results were extracted in standardized tables by one reviewer and checked by a second reviewer.
RESULTS: Six controlled studies were included. Only one study was randomized. The study quality was moderate to low. One study showed statistically significant results in favor of the adherence intervention, two studies showed a tendency in favor of the intervention, one study showed an inconsistent result depending on the adherence definition and one study showed almost identical adherence rates in both groups. One study showed a tendency in favor of the control group.
CONCLUSIONS: Although most of the interventions are not very effective, it appears that certain adherence enhancing interventions could have a promising effect. One crucial point is the consideration of the baseline adherence when choosing patients to avoid ceiling effects. The evidence is limited due to lack of sufficient studies and partly inconsistent results. Further high quality studies are needed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Medication adherence; Neoplasms; Oncology; Oral anticancer agents; Oral chemotherapy; Patient compliance

Mesh:

Substances:

Year:  2013        PMID: 23910455     DOI: 10.1016/j.ctrv.2013.07.004

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  27 in total

1.  It's not an easy fix: Adherence to adjuvant endocrine therapy after breast cancer.

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard
Journal:  Can Oncol Nurs J       Date:  2021-05-01

2.  Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.

Authors:  Shirley M Bluethmann; Caitlin C Murphy; Jasmin A Tiro; Michelle A Mollica; Sally W Vernon; Leona Kay Bartholomew
Journal:  Oncol Nurs Forum       Date:  2017-05-01       Impact factor: 2.172

3.  Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.

Authors:  Evelina Cardoso; Chantal Csajka; Marie P Schneider; Nicolas Widmer
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

Review 4.  Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.

Authors:  Megan C Roberts; Stephanie B Wheeler; Katherine Reeder-Hayes
Journal:  Am J Public Health       Date:  2015-04-23       Impact factor: 9.308

5.  Temporary Stoppages and Burden of Treatment in Patients With Cancer.

Authors:  Eric Vachon; Barbara Given; Charles Given; Susann Dunn
Journal:  Oncol Nurs Forum       Date:  2019-09-01       Impact factor: 2.172

6.  NICSO: Network Italiano Cure di Supporto in Oncologia--Italian Network for Supportive Care in Oncology.

Authors:  Fausto Roila; Carla Ida Ripamonti; Andrea Antonuzzo; Paolo Bossi
Journal:  Support Care Cancer       Date:  2014-10-16       Impact factor: 3.603

Review 7.  A Systematic Review of Adherence to Oral Antineoplastic Therapies.

Authors:  Joseph A Greer; Nicole Amoyal; Lauren Nisotel; Joel N Fishbein; James MacDonald; Jamie Stagl; Inga Lennes; Jennifer S Temel; Steven A Safren; William F Pirl
Journal:  Oncologist       Date:  2016-02-26

8.  The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.

Authors:  Gang Zhang; Dongwei Guo; Prasanta K Dash; Mariluz Araínga; Jayme L Wiederin; Nicole A Haverland; Jaclyn Knibbe-Hollinger; Andrea Martinez-Skinner; Pawel Ciborowski; Val S Goodfellow; Tadeusz A Wysocki; Beata J Wysocki; Larisa Y Poluektova; Xin-Ming Liu; JoEllyn M McMillan; Santhi Gorantla; Harris A Gelbard; Howard E Gendelman
Journal:  Nanomedicine       Date:  2015-10-22       Impact factor: 5.307

9. 

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard
Journal:  Can Oncol Nurs J       Date:  2021-05-01

10.  The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.

Authors:  Joan M Neuner; Nicole M Fergestrom; Purushottam W Laud; Ann B Nattinger; Kirsten M M Beyer; Kathryn E Flynn; Liliana E Pezzin
Journal:  Cancer       Date:  2019-08-02       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.